ALDARA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ALDARA (ALDARA).
Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates immune cells, leading to the production of cytokines such as interferon-alpha, which promotes antiviral and antitumor activity.
| Metabolism | Metabolized via oxidation to inactive metabolites; extensively distributed with no specific enzyme pathway identified; renal excretion of metabolites. |
| Excretion | Renal: negligible; biliary/fecal: 94% as unchanged drug and metabolites |
| Half-life | Terminal half-life: 2-4 hours after topical application; no systemic accumulation with once-daily dosing |
| Protein binding | Approximately 96% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | Vd: 2.5-3.0 L/kg, indicating extensive tissue distribution |
| Bioavailability | Topical: minimal systemic absorption (<0.1% of applied dose); oral: not applicable |
| Onset of Action | Topical: clinical response (erythema, edema, erosion) typically within 2-4 weeks of daily application |
| Duration of Action | Duration: depends on treatment course; typically 4-16 weeks; lesions may continue to clear for up to 4 weeks after treatment cessation |
Apply a thin layer to the target lesion(s) 3 times per week (e.g., Monday, Wednesday, Friday) for up to 16 weeks. Do not occlude. Wash hands before and after application.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. |
| Geriatric use | No specific dose adjustment recommended; use caution due to potential increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ALDARA (ALDARA).
| Breastfeeding | M/P ratio not determined. It is not known whether imiquimod is excreted in human milk. Due to unknown risks to the nursing infant, caution should be exercised. Most guidelines recommend avoiding use on the breast area during breastfeeding. If applied elsewhere, ensure infant does not contact the application site. |
| Teratogenic Risk | There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Imiquimod (ALDARA) is not recommended for use during pregnancy due to potential risk of systemic absorption; fetal risk cannot be excluded. Increased risk of preterm birth or low birth weight has not been specifically associated. The drug should be used during pregnancy only if clearly needed and if potential benefit justifies potential risk to the fetus. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to imiquimod or any component of the formulation"]
| Precautions | ["Flu-like systemic symptoms may occur (fever, myalgias, headache)","Local skin reactions (erythema, erosion, flaking) are common","Not recommended for treatment of urethral, intravaginal, cervical, or intra-anal warts","Avoid use in patients with pre-existing autoimmune conditions (limited data)","Avoid contact with eyes, lips, and nostrils"] |
| Food/Dietary | No known food interactions. |
| Clinical Pearls |
Loading safety data…
| Fetal Monitoring | No specific fetal monitoring required. Monitor for signs of maternal systemic absorption (e.g., flu-like symptoms, leukopenia) if applied to large areas or under occlusion. No requirement for serial fetal ultrasound unless clinical indication. |
| Fertility Effects | Imiquimod did not affect fertility in animal studies at doses up to 5 mg/kg/day (approximately 16 times the recommended human dose based on body surface area). No human data on fertility effects. Limited impact expected. |
| Apply at bedtime and wash off after 6-10 hours. Avoid contact with eyes, lips, and nostrils. Local skin reactions (erythema, edema, vesicles) are common and indicate immune response. Do not use on open wounds or compromised skin. Consider treatment breaks for severe reactions. |
| Patient Advice | Wash hands before and after applying the cream. · Apply a thin layer to the lesion and rub in gently. · Do not cover the area with bandages or dressings unless instructed. · Avoid sexual contact if applied to genital or anal areas. · Store at room temperature, away from heat and light. |